Progyny, Inc. (NASDAQ:PGNY) Stock Position Lessened by Bullseye Asset Management LLC

Bullseye Asset Management LLC lowered its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 95.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,400 shares of the company's stock after selling 77,865 shares during the period. Bullseye Asset Management LLC's holdings in Progyny were worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Quarry LP lifted its position in shares of Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company's stock worth $25,000 after buying an additional 836 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Progyny during the second quarter worth $44,000. Mendota Financial Group LLC acquired a new position in shares of Progyny during the 3rd quarter worth $56,000. Meeder Asset Management Inc. purchased a new position in Progyny in the third quarter valued at about $77,000. Finally, 1620 Investment Advisors Inc. purchased a new position in Progyny in the 2nd quarter valued at approximately $97,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Trading Down 0.6 %

NASDAQ PGNY traded down $0.10 on Tuesday, hitting $15.74. 1,645,784 shares of the stock traded hands, compared to its average volume of 1,401,484. The stock has a 50-day moving average of $15.60 and a 200 day moving average of $21.55. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $42.08. The company has a market capitalization of $1.34 billion, a P/E ratio of 27.14, a price-to-earnings-growth ratio of 1.66 and a beta of 1.35.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 EPS. As a group, equities research analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PGNY shares. Truist Financial restated a "hold" rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Canaccord Genuity Group dropped their target price on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $17.00 price target (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Leerink Partners reduced their price objective on Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research note on Thursday, September 19th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of Progyny in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $25.00.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.